Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

Robert M. Jotte,Jerome H. Goldschmidt,Jeffrey Gary Schneider,Merrill Kingman Shum,David Berz,Lasika C. Seneviratne,Matei P. Socoteanu,Annie Hung,Rebecca R. Hozak,Bo H. Chao,John Nemunaitis

Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).

2020

Robert M. Jotte
Jerome H. Goldschmidt
Jeffrey Gary Schneider
Merrill Kingman Shum
David Berz
Lasika C. Seneviratne
Matei P. Socoteanu
Annie Hung
Rebecca R. Hozak
Bo H. Chao
John Nemunaitis

e21744Background: Nivolumab (N) is an immune checkpoint inhibitor (CPI) approved to treat post-platinum NSCLC as monotherapy. PEG in combination with N has demonstrated promising efficacy in NSCLC ...

Keywords:

Oncology
PEG ratio
Internal medicine
Nivolumab
Pathology
in patient
pd l1 expression
Phases of clinical research
Immunotherapy
Platinum
Cypress
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations